• Semaglutide and Heart Failure with Preserved Ejection Fraction: Key Findings

  • Jan 12 2025
  • Length: 17 mins
  • Podcast

Semaglutide and Heart Failure with Preserved Ejection Fraction: Key Findings

Listen for free

View show details

  • Summary

  • In this episode of the Heartbeat Podcast, we delve into the latest findings from a pooled analysis of pivotal clinical trials—SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM. This study uncovers the impact of semaglutide, a GLP-1 receptor agonist, on patients with heart failure with preserved ejection fraction (HFpEF), particularly those struggling with obesity. Join us as we explore how this treatment reduces heart failure events and discuss its implications for clinical practice. With HFpEF being a challenging condition to treat, this episode highlights hope for patients and clinicians alike.

    Stay tuned for an insightful discussion, statistics, and the potential future of HFpEF management!

    Listen to the Episode Here:

    • Apple Podcasts: Heartbeat Podcast on Apple
    • Spotify: Heartbeat Podcast on Spotify
    • Amazon Music: Heartbeat Podcast on Amazon
    • YouTube: Heartbeat Podcast on YouTube


    #HFpEF #HeartFailure #Semaglutide #MedicalResearch #Cardiology #HeartHealth #Obesity #Podcast #MedicalScience #GLP1ReceptorAgonist#SELECTStudy #FLOWTrial #STEP_HFpEF #STEP_HFpEF_DM


    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Semaglutide and Heart Failure with Preserved Ejection Fraction: Key Findings

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available